Title
Category
Credits
Event date
Cost
  • Participation
$0.00
  • Participation
$0.00
Depression and anxiety disorders commonly occur among patients with cancer and their family caregivers. This lecture focuses on the common symptoms and management strategies for depression and anxiety disorders in patients with cancer and their family members.
  • Participation
$0.00
In this presentation, Dr. Wood and Dr. Battaglini will review the importance of physical function (also referred to as physical performance) in patients receiving treatment for cancer, followed by a review of the mechanisms and evidence base supporting the role of exercise in improving cancer outcomes. Examples of aerobic and resistance exercise interventions will be discussed.
  • Participation
$0.00
Glioblastoma is a devastating disease with a survival that is measured in months. The recent FDA approval of the Optune device for the treatment of newly-diagnosed glioblastoma was a paradigm shift in the field of neuro-oncology. We will focus our discussion on the biological underpinnings of this device and clinical data supporting its use.
  • Participation
$0.00
The gut microbiome is responsible for regulation of many functions in humans including metabolism, immune responses and inflammation. This lecture will focus on the gut microbiome and their interactions with the host to influence cancer treatment outcomes.
  • Participation
$0.00
Treatment of metastatic colorectal cancer has continued to evolve over the last several years, with emerging identification of biomarkers that underlie heterogeneity of responses to new and existing therapy. Ongoing clinical research seeks to identify new therapeutic options in molecularly-defined subgroups of patients. We will review the most exciting and clinically impactful research findings in this presentation.
  • Participation
$0.00
Lisa Carey, MD, will discuss the anatomic and genomic variables that impact on (neo)adjuvant decision-making in breast cancer and the current treatment algorithms that allow rational escalation and de-escalation of systemic therapy.

Pages